Tyra Biosciences Files 2023 Annual Report on Form 10-K

Ticker: TYRA · Form: 10-K · Filed: Mar 19, 2024 · CIK: 1863127

Tyra Biosciences, Inc. 10-K Filing Summary
FieldDetail
CompanyTyra Biosciences, Inc. (TYRA)
Form Type10-K
Filed DateMar 19, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Tyra Biosciences, Annual Report, Pharmaceuticals, SEC Filing

TL;DR

<b>Tyra Biosciences, Inc. has filed its 2023 10-K report detailing its fiscal year operations and financial standing.</b>

AI Summary

Tyra Biosciences, Inc. (TYRA) filed a Annual Report (10-K) with the SEC on March 19, 2024. Tyra Biosciences, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. Key dates mentioned include December 31, 2023, as the fiscal year end and March 19, 2024, as the filing date. The company's principal business address is located at 2656 State Street, Carlsbad, CA 92008. Tyra Biosciences, Inc. is classified under the SIC code 2834 for Pharmaceutical Preparations.

Why It Matters

For investors and stakeholders tracking Tyra Biosciences, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Tyra Biosciences' financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial information and risk factors disclosed in the 10-K are essential for investors and stakeholders to understand the company's current position, potential challenges, and regulatory compliance.

Risk Assessment

Risk Level: medium — Tyra Biosciences, Inc. shows moderate risk based on this filing. The company is in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, clinical trial risks, and market competition, as indicated by its SIC code and the nature of its business.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Tyra Biosciences' current financial health and strategic outlook.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Conformed Period of Report)
  • 2024-03-19 — Filing Date (Filed as of Date)
  • 2834 — SIC Code (Pharmaceutical Preparations)
  • 001-40800 — SEC File Number (SEC Filing Details)

Key Players & Entities

  • Tyra Biosciences, Inc. (company) — Filer name
  • 0000950170-24-033461 (other) — Accession Number
  • 20231231 (date) — Conformed Period of Report
  • 20240319 (date) — Filed as of Date
  • 2834 (other) — Standard Industrial Classification
  • DE (other) — State of Incorporation
  • Carlsbad, CA (location) — Business Address City/State
  • 001-40800 (other) — SEC File Number

FAQ

When did Tyra Biosciences, Inc. file this 10-K?

Tyra Biosciences, Inc. filed this Annual Report (10-K) with the SEC on March 19, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Tyra Biosciences, Inc. (TYRA).

Where can I read the original 10-K filing from Tyra Biosciences, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Tyra Biosciences, Inc..

What are the key takeaways from Tyra Biosciences, Inc.'s 10-K?

Tyra Biosciences, Inc. filed this 10-K on March 19, 2024. Key takeaways: Tyra Biosciences, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The filing covers the period from January 1, 2023, to December 31, 2023.. Key dates mentioned include December 31, 2023, as the fiscal year end and March 19, 2024, as the filing date..

Is Tyra Biosciences, Inc. a risky investment based on this filing?

Based on this 10-K, Tyra Biosciences, Inc. presents a moderate-risk profile. The company is in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, clinical trial risks, and market competition, as indicated by its SIC code and the nature of its business.

What should investors do after reading Tyra Biosciences, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand Tyra Biosciences' current financial health and strategic outlook. The overall sentiment from this filing is neutral.

Key Dates

  • 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
  • 2024-03-19: Filing Date — Date the 10-K was officially submitted to the SEC.

Filing Stats: 4,375 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-03-19 16:09:27

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TYRA The Nasdaq

Filing Documents

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 58 Item 1B. Unresolved Staff Comments 122 Item 1C. Cybersecurity 123 Item 2.

Properties

Properties 124 Item 3.

Legal Proceedings

Legal Proceedings 124 Item 4. Mine Safety Disclosures 124 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 125 Item 6. [Reserved] 126 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 127 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 136 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 137 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 160 Item 9A.

Controls and Procedures

Controls and Procedures 160 Item 9B. Other Information 161 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 161 PART III Item 10. Directors, Executive Officers and Corporate Governance 161 Item 11.

Executive Compensation

Executive Compensation 161 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 161 Item 13. Certain Relationships and Related Transactions, and Director Independence 162 Item 14. Principal Accounting Fees and Services 162 PART IV Item 15. Exhibits and Financial Statement Schedules 162 Item 16. Form 10-K Summary 162 1 PART I

FORWARD-LOOKING STATEMENTS AND MARKET DATA

FORWARD-LOOKING STATEMENTS AND MARKET DATA This Annual Report on Form 10-K (Annual Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing and phase of development, costs, design and conduct of our ongoing and planned preclinical studies and clinical trials for our product candidates, the potential benefits of regulatory designations, the timing and likelihood of regulatory filings and approvals for our product candidates, the potential to develop product candidates and the safety and therapeutic benefits of our product candidates, our ability to commercialize our product candidates, if approved, the pricing and reimbursement of our product candidates, if approved, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This Annual Report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future perform

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.